Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.).
作者信息
Rhee Sang Youl
机构信息
Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
出版信息
Endocrinol Metab (Seoul). 2020 Mar;35(1):192-193. doi: 10.3803/EnM.2020.35.1.192.
Abstract
摘要
相似文献
1
Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.).信函：成人 2 型糖尿病患者从基础胰岛素转换为每日一次德谷胰岛素/门冬胰岛素后血糖控制良好（2019 年；34：382 - 389，Han Na Jang 等人）
Endocrinol Metab (Seoul). 2020 Mar;35(1):192-193. doi: 10.3803/EnM.2020.35.1.192.
2
Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.).回应：2型糖尿病成人患者从基础胰岛素转换为每日一次德谷胰岛素/门冬胰岛素后血糖得到良好控制（2019年；34:382 - 389，Han Na Jang等人）
Endocrinol Metab (Seoul). 2020 Mar;35(1):194-195. doi: 10.3803/EnM.2020.35.1.194.
3
Clinical use of the co-formulation of insulin degludec and insulin aspart.德谷胰岛素与门冬胰岛素复方制剂的临床应用
Int J Clin Pract. 2016 Aug;70(8):657-67. doi: 10.1111/ijcp.12821. Epub 2016 Jul 7.
4
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).一项比较利拉鲁肽与门冬胰岛素每日 1 次添加至德谷胰岛素在 2 型糖尿病患者中的疗效的研究（BEGIN：VICTOZA ADD-ON）。
Diabetes Obes Metab. 2014 Jul;16(7):636-44. doi: 10.1111/dom.12262. Epub 2014 Feb 11.
5
Premix insulins in type 1 diabetes: the coming of degludec/aspart.预混胰岛素在 1 型糖尿病中的应用：地特胰岛素/门冬胰岛素的问世。
Expert Opin Drug Metab Toxicol. 2019 Apr;15(4):341-348. doi: 10.1080/17425255.2019.1585427. Epub 2019 Mar 18.
6
Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.在1型糖尿病患者中，德谷胰岛素在每日血糖变异性方面优于甘精胰岛素。
Endocr J. 2016;63(1):53-60. doi: 10.1507/endocrj.EJ15-0438. Epub 2015 Oct 31.
7
Insulin Degludec/Insulin Aspart: A Novel Co-formulation for Insulin Intensification.德谷胰岛素/门冬胰岛素：一种用于强化胰岛素治疗的新型复方制剂。
J Assoc Physicians India. 2015 May;63(5 Suppl):6-7.
8
A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.德谷胰岛素/门冬胰岛素综述：药代动力学和药效学特性及其在临床应用中的意义
Clin Pharmacokinet. 2017 Apr;56(4):339-354. doi: 10.1007/s40262-016-0455-7.
9
Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes.每日三次门冬胰岛素与每日一次地特胰岛素对 2 型糖尿病患者氧化应激影响的比较。
Endocr J. 2011;58(12):1055-63. doi: 10.1507/endocrj.k11e-114. Epub 2011 Oct 8.
10
Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.德谷胰岛素，一种用于 1 型和 2 型糖尿病的长效每日一次基础胰岛素类似物。
Can J Diabetes. 2015 Feb;39(1):4-9. doi: 10.1016/j.jcjd.2014.02.019. Epub 2014 Jul 22.
本文引用的文献
1
Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.在 2 型糖尿病成人中从基础胰岛素转换为每日一次德谷胰岛素/门冬胰岛素后的血糖良好控制。
Endocrinol Metab (Seoul). 2019 Dec;34(4):382-389. doi: 10.3803/EnM.2019.34.4.382.
2
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.度拉糖肽与 2 型糖尿病患者的心血管结局（REWIND）：一项双盲、随机、安慰剂对照试验。
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
3
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.利西拉来（甘精胰岛素和利西那肽的可滴定固定比例复方制剂）对比甘精胰岛素和利西那肽单药治疗在口服药物控制不佳的 2 型糖尿病患者中的疗效：LixiLan-O 随机试验。
Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15.
4
Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.界定血浆葡萄糖与糖化血红蛋白（HbA₁c）之间的关系：糖尿病控制与并发症试验中葡萄糖谱和糖化血红蛋白（HbA₁c）的分析
Diabetes Care. 2002 Feb;25(2):275-8. doi: 10.2337/diacare.25.2.275.
Zotero 插件